Passage Bio (PASG) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Tempest Therapeutics (TPST) over the past year, losing 54.3% versus a loss of 93.0%. Over five years, PASG leads with a -98.1% price change compared with -99.6% for TPST. Tempest Therapeutics is the larger company by market cap ($13.0 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PASG | TPST |
|---|---|---|
| Share price | $3.78 | $0.77 |
| Market cap | $12.16M | $13.01M |
| 1-day change | -1.95% | -2.70% |
| YTD return | -67.97% | -73.17% |
| 1-year return | -54.35% | -92.99% |
| 5-year return | -98.06% | -99.60% |
| EPS (TTM) | $-11.55 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.00 | $12.23 |
| 52-week low | $3.29 | $0.743 |
| Distance from 52-week high | -81.10% | -93.70% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +310.05% | +809.09% |
| Average volume | 26.11K | 2.60M |
| Shares outstanding | 3.22M | 16.89M |
| Employees | 24 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed TPST by 38.6 percentage points over the past year.
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Healthcare · Biotechnology · 4 employees
PASG vs TPST FAQ
Which is bigger, Passage Bio or Tempest Therapeutics?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $13.01M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, PASG or TPST?
PASG returned -54.35% over the past 12 months, compared with -92.99% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Passage Bio and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.